| Not Yet Recruiting | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NCT07516093 | Nurix Therapeutics, Inc. | Phase 3 |
| Not Yet Recruiting | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006 | Nurix Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors NCT07526597 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemi NCT07218510 | City of Hope Medical Center | Phase 2 |
| Recruiting | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL NCT07014917 | Zulfa Omer | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Mosunetuzumab for CLL MRD Clearance NCT07052695 | Inhye Ahn | Phase 1 / Phase 2 |
| Recruiting | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Ch NCT06520098 | VA Office of Research and Development | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Ref NCT06973187 | BeOne Medicines | Phase 3 |
| Recruiting | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998 | Zulfa Omer | Phase 2 |
| Withdrawn | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalab NCT06839872 | AstraZeneca | Phase 2 |
| Recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituxi NCT06943872 | BeOne Medicines | Phase 3 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lym NCT06839053 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of NCT06978088 | Zulfa Omer | Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lympho NCT06970743 | BeOne Medicines | Phase 3 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | 64Cu-LLP2A for Imaging Hematologic Malignancies NCT06636175 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relaps NCT06291220 | AbbVie | Phase 1 |
| Recruiting | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chroni NCT06588478 | Loxo Oncology, Inc. | Phase 2 |
| Recruiting | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BT NCT06466122 | Kerry Rogers | Phase 2 |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias NCT06364423 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Ly NCT06544785 | PETHEMA Foundation | Phase 2 |
| Not Yet Recruiting | Biological and Clinical Efficacy of Shingrix in Patients With CLL NCT06364033 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Not Yet Recruiting | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL NCT06367374 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocyt NCT05963074 | Janssen Research & Development, LLC | Phase 2 |
| Withdrawn | Cardiotoxicities in Patients Receiving BTKi NCT05521178 | Dana-Farber Cancer Institute | — |
| Recruiting | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia NCT06333262 | Inhye Ahn | Phase 2 |
| Active Not Recruiting | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic NCT06547944 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in NCT06136559 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL NCT05694312 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chroni NCT05959694 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia NCT05417165 | Seema Bhat | Phase 2 |
| Recruiting | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363 | Carna Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia o NCT05718869 | City of Hope Medical Center | Phase 2 |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic NCT05624554 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia NCT05677919 | Mayo Clinic | Phase 2 |
| Recruiting | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic NCT05371808 | Canadian Cancer Trials Group | — |
| Recruiting | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic NCT05388006 | Mayo Clinic | Phase 2 |
| Terminated | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small NCT05317936 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocyt NCT05479994 | BeiGene | Phase 2 |
| Recruiting | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymp NCT05336812 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/S NCT05254743 | Loxo Oncology, Inc. | Phase 3 |
| Terminated | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL NCT05272813 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL NCT05287984 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Recruiting | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associa NCT05183854 | University of Utah | Phase 2 |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Recruiting | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467 | Ascentage Pharma Group Inc. | Phase 2 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Recruiting | Study on the Diagnosis and Management of CLL in Italy by GIMEMA NCT04867915 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Active Not Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic NCT05023980 | Loxo Oncology, Inc. | Phase 3 |
| Active Not Recruiting | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) i NCT04965493 | Loxo Oncology, Inc. | Phase 3 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Active Not Recruiting | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL NCT04722172 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Active Not Recruiting | A Study of FCN-338 in Patients With Chronic CLL/SLL NCT04682808 | Fochon Pharmaceuticals, Ltd. | Phase 1 |
| Active Not Recruiting | Safe Accelerated Venetoclax Escalation in CLL NCT04843904 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymph NCT04852822 | University of Washington | — |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Active Not Recruiting | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus NCT04666038 | Loxo Oncology, Inc. | Phase 3 |
| Recruiting | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Le NCT04269902 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced NCT04504708 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL NCT04578613 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lym NCT04694560 | Memorial Sloan Kettering Cancer Center | — |
| Active Not Recruiting | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL NCT04624633 | Jennifer R. Brown, MD, PhD | Phase 2 |
| Terminated | Study of LUCAR-20S in Patients With R/R NHL NCT04176913 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and NCT04623541 | Genmab | Phase 1 / Phase 2 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 NCT04665115 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL NCT04560322 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324 | Virginia Commonwealth University | Phase 1 |
| Terminated | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, NCT04553692 | IGM Biosciences, Inc. | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Recruiting | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL NCT04494503 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia NCT04505254 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies NCT04279405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Completed | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195 | Precision BioSciences, Inc. | Phase 1 / Phase 2 |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Completed | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL NCT04155710 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Terminated | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or NCT04155840 | University of Washington | Phase 2 |
| Completed | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma NCT03892044 | David Bond, MD | Phase 1 |
| Unknown | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice NCT04094051 | The First Affiliated Hospital with Nanjing Medical University | — |
| Terminated | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma NCT03828448 | TG Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL NCT03960840 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL NCT03572634 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared NCT03801525 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Terminated | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas NCT03893682 | Aptose Biosciences Inc. | Phase 1 |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL NCT03740529 | Loxo Oncology, Inc. | Phase 1 / Phase 2 |
| Recruiting | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra NCT03666000 | Imugene Limited | Phase 1 |
| Active Not Recruiting | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymph NCT03701282 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab NCT03737981 | National Cancer Institute (NCI) | Phase 3 |
| Completed | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocyt NCT03734016 | BeiGene | Phase 3 |
| Recruiting | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia NCT03516617 | Mayo Clinic | Phase 2 |
| Terminated | A Study Of The Selective PKC-β Inhibitor MS- 553 NCT03492125 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib NCT03422393 | Michael Choi | Phase 1 |
| Completed | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901 | Ronald Levy | Phase 1 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) NCT04771507 | Jeanette Lundin | Phase 1 / Phase 2 |
| Withdrawn | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic NCT03370185 | SecuraBio | Phase 2 |
| Completed | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies NCT03088878 | Oncternal Therapeutics, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL NCT03336333 | BeiGene | Phase 3 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Completed | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation NCT03133221 | University of Maryland, Baltimore | Phase 2 |
| Completed | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell NCT03019055 | Medical College of Wisconsin | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma NCT03078855 | Jonathan Friedberg | Phase 3 |
| Completed | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma NCT03035331 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom NCT02952508 | Cellectar Biosciences, Inc. | Phase 2 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Terminated | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers NCT03037645 | Sunesis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymph NCT02846623 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL NCT02639910 | MorphoSys AG | Phase 2 |
| Completed | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lym NCT02910583 | Pharmacyclics LLC. | Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Unknown | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy W NCT02825836 | Telios Pharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia NCT02756897 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Smal NCT02640833 | AbbVie | Phase 1 |
| Terminated | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL NCT02784834 | Michael Choi | Phase 1 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisi NCT02793583 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Active Not Recruiting | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma NCT02339922 | University of Washington | Phase 2 |
| Active Not Recruiting | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphoc NCT02629809 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphoc NCT02518555 | Jennifer Woyach | Phase 2 |
| Completed | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies NCT02529813 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly NCT02623920 | University of Arizona | Phase 2 |
| Active Not Recruiting | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL NCT02514083 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Withdrawn | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab a NCT02576275 | SecuraBio | Phase 3 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Ly NCT02258529 | Gilead Sciences | Phase 2 |
| Completed | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL NCT02337829 | Acerta Pharma BV | Phase 2 |
| Terminated | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Foll NCT02258555 | Gilead Sciences | Phase 1 |
| Completed | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL NCT02296918 | Acerta Pharma BV | Phase 1 |
| Completed | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relap NCT02242045 | Gilead Sciences | Phase 1 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL NCT02135133 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CL NCT02200848 | Georgetown University | Phase 1 |
| Active Not Recruiting | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patie NCT02048813 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | A Phase II Study of Doxycycline in Relapsed NHL NCT02086591 | University of Rochester | Phase 2 |
| Terminated | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) NCT02046928 | Ångstrom Pharmaceuticals | Phase 2 |
| Active Not Recruiting | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic NCT02029443 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Withdrawn | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocyti NCT01724346 | Pharmacyclics LLC. | Phase 3 |
| Completed | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Stud NCT02049515 | SecuraBio | Phase 3 |
| Completed | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreate NCT01754857 | University of Wisconsin, Madison | Phase 2 |
| Completed | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) NCT02004522 | SecuraBio | Phase 3 |
| Completed | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma NCT01973387 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients NCT01862445 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | A Long-term Extension Study of PCI-32765 (Ibrutinib) NCT01804686 | Janssen Research & Development, LLC | Phase 3 |
| Completed | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction NCT01832922 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Active Not Recruiting | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409 | Mayo Clinic | N/A |
| Completed | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL NCT01722487 | Pharmacyclics LLC. | Phase 3 |
| Terminated | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL NCT01728207 | Gilead Sciences | Phase 1 |
| Completed | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL NCT01400685 | Massachusetts General Hospital | Phase 1 |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 | TG Therapeutics, Inc. | Phase 1 |
| Completed | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Smal NCT01650727 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Ch NCT01611090 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma NCT01699152 | Tragara Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects W NCT01682616 | AbbVie | Phase 1 |
| Completed | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lym NCT01578707 | Pharmacyclics LLC. | Phase 3 |
| Completed | Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/ NCT01496976 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia NCT01497496 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukem NCT01351896 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) NCT01419691 | University of Kansas Medical Center | Phase 2 |
| Completed | Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014 | University of Rochester | Phase 2 |
| Completed | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas NCT01282424 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymph NCT01306643 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bend NCT01292135 | Pharmacyclics LLC. | Phase 1 |
| Terminated | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic NCT01446900 | European Institute of Oncology | Phase 2 |
| Completed | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma NCT01239394 | Massachusetts General Hospital | Phase 2 |
| Completed | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL NCT01217749 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell NCT01239875 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia NCT01161511 | Xencor, Inc. | Phase 1 |
| Completed | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT01113632 | SCRI Development Innovations, LLC | Phase 2 |
| Terminated | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL NCT01173679 | Massachusetts General Hospital | Phase 2 |
| Completed | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL NCT01145209 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL NCT01241786 | Hackensack Meridian Health | Phase 2 |
| Completed | A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymp NCT01117142 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Completed | Safety of PCI-32765 in Chronic Lymphocytic Leukemia NCT01105247 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Terminated | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) NCT01010568 | Georgetown University | Phase 2 |
| Completed | Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or S NCT01002755 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and NCT00974233 | University of Wisconsin, Madison | Phase 2 |
| Completed | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT00873457 | Daphne Friedman | Phase 2 |
| Terminated | Study of Repeat Intranodal Injections of Ad-ISF35 NCT00942409 | Januario Castro, M.D. | Phase 2 |
| Terminated | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocyti NCT00849524 | Januario Castro, M.D. | Phase 2 |
| Completed | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia NCT00759603 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Recruiting | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic NCT00923507 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older NCT00535873 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT00439231 | Georg Aue, M.D. | Phase 2 |
| Completed | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. NCT00801281 | Polish Lymphoma Research Group | Phase 3 |
| Completed | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leuk NCT00850057 | University of California, San Diego | Phase 1 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic NCT00290004 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malig NCT00275431 | Ascenta Therapeutics | Phase 2 |
| Completed | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma NCT01000753 | Children's Oncology Group | — |
| Completed | Unrelated Donor Stem Cell Transplantation NCT01364363 | Scripps Health | N/A |
| Terminated | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom NCT00100711 | Pharmacyclics LLC. | Phase 2 |
| Completed | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT00193518 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma NCT00201682 | John Byrd | Phase 1 / Phase 2 |
| Terminated | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia NCT00022971 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia NCT00234481 | Exelixis | Phase 1 |